Name: SB505124
Price: 289.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    SB505124 is a selective and small molecule inhibitor of transforming growth Factor- β type 1 receptors ALK4, ALK5 and ALK7 with the IC50 values of 129±11nM and 47±5nM for ALK4 and ALK5, respectively. [1].SB505124 has been reported as a potent inhibitor of the in vitro kinase activity of ALK4, ALK5 and ALK7 for its substrate Smad3. In addition, SB505124 has been revealed to be a reversible ATP competitive inhibitor. Moreover, SB505124 has shown no toxicity to renal epithelial A498 cells at concentrations up to 100μM for 48 h. Furthermore, SB505124 has been demonstrated to restrain the TGF-β-induced phosphorylation of Smad2 in three cell lines (HepG2 human hepatoma cells, C2C12 mouse myoblasts and Mv1Lu mink lung cells) in a concentration-dependent manner [1].
    
    [1] DaCosta Byfield S1, Major C, Laping NJ, Roberts AB. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2004 Mar;65(3):744-52.
- Properties
  - Alternative Name
    
    2-[4-(1,3-benzodioxol-5-yl)-2-tert-butyl-1H-imidazol-5-yl]-6-methylpyridine
    
    CAS Number
    
    694433-59-5
    
    Molecular Formula
    
    C20H21N3O2
    
    Molecular Weight
    
    335.4
    
    Purity
    
    98.00%
    
    Solubility
    
    ≥33.5 mg/mL in DMSO; ≥14.93 mg/mL in EtOH; ≥2.18 mg/mL in H2O with gentle warming and ultrasonic
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only